Abstract

Mycobacterium abscessus is a member of the non-tuberculous mycobacteria (NTM) group, responsible for chronic infections in individuals with cystic fibrosis (CF) or those otherwise immunocompromised. While viewed traditionally as an opportunistic pathogen, increasing research into M. abscessus in recent years has highlighted its continued evolution into a true pathogen. This is demonstrated through an extensive collection of virulence factors (VFs) possessed by this organism which facilitate survival within the host, particularly in the harsh environment of the CF lung. These include VFs resembling those of other Mycobacteria, and non-mycobacterial VFs, both of which make a notable contribution in shaping M. abscessus interaction with the host. Mycobacterium abscessus continued acquisition of VFs is cause for concern and highlights the need for novel vaccination strategies to combat this pathogen. An effective M. abscessus vaccine must be suitably designed for target populations (i.e., individuals with CF) and incorporate current knowledge on immune correlates of protection against M. abscessus infection. Vaccination strategies must also build upon lessons learned from ongoing efforts to develop novel vaccines for other pathogens, particularly Mycobacterium tuberculosis (M. tb); decades of research into M. tb has provided insight into unconventional and innovative vaccine approaches that may be applied to M. abscessus. Continued research into M. abscessus pathogenesis will be critical for the future development of safe and effective vaccines and therapeutics to reduce global incidence of this emerging pathogen.

Highlights

  • The Mycobacterium abscessus clade are an emerging group of prominent human pathogens

  • The M. abscessus clade is problematic for individuals with enhanced susceptibility to pulmonary infection, such as those with bronchiectasis or chronic obstructive pulmonary disease (COPD), prior tuberculosis (TB) infection, or individuals with cystic fibrosis (CF; Griffith et al, 2007)

  • We have elevated our understanding of M. abscessus from a relatively innocuous environmental organism to a formidable evolving true pathogen with a range of immune modulatory mechanisms to facilitate its survival within the host

Read more

Summary

Introduction

The Mycobacterium abscessus clade are an emerging group of prominent human pathogens. Mycobacterium abscessus infection is extremely difficult to treat due to intrinsic, adaptive, and acquired antibiotic resistance traits; these result in poor treatment success rates as low as 30% depending on the subspecies (Nessar et al, 2012; Koh et al, 2014). Despite the significant impact of M. abscessus infection on susceptible populations, there is currently no vaccine available (approved or within clinical trials) for M. abscessus. Given both the difficulty in treating M. abscessus and the poor prognosis following the establishment of persistent and chronic infection, there is an urgent need to develop novel prophylactic interventions to reduce incidence of M. abscessus infections in at-risk populations

Objectives
Findings
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.